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S U M M A R Y
Background: West Nile fever is an important zoonotic infection caused by West Nile virus (WNV), a
member of the Flaviviridae. Previous serological data from Turkey suggest widespread WNV circulation.
This report includes cases of human and equine WNV infections occurring concurrently, and manifesting
as central nervous system infections, in two neighboring provinces of Central Anatolia, Turkey. A partial
phylogenetic analysis of the causative virus is given for the ﬁrst time.
Methods: The cases were reported in February (horses) and March (human). Symptoms of the disease
were similar in the two species, characterized by neurological manifestations suggesting meningoen-
cephalitis. Real-time/nested PCRs and commercial immunoassays and a plaque reduction neutralization
assay were employed for the detection of viral RNA and speciﬁc antibodies, respectively.
Results: WNV RNAs were detected in buffy coat (horses) and cerebrospinal ﬂuid (human) samples. Partial
nucleotide sequences of the E-gene coding region revealed that the strains are closely related to viruses of
lineage 1, clade 1a. Accompanying equine serosurveillance demonstrated WNV-speciﬁc antibodies in
31.6% of the samples.
Conclusions: This is the ﬁrst report of acute WNV infections caused by lineage 1 strains from Turkey, in
concordance with previous reports from some European and North African countries.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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West Nile virus (WNV) is an arthropod-borne ﬂavivirus affecting
a wide range of vertebrates, including birds and mammals.1 The
natural cycle of infection involves birds and mosquitoes of the Culex
family; humans and horses are considered dead-end hosts. The
transmission of WNV to susceptible individuals frequently requires
the bites of infected culicine mosquitoes.1,2 Although the majority of
infections are mild or asymptomatic, WNV may cause outbreaks of
febrile disease and encephalitis in humans and horses.2 While less
than 1% of human cases experience severe disease, up to 90% of
symptomatic cases in horses result in a neurological disease with
case-fatality rates of 30–40%.2–5 Initially identiﬁed in tropical Africa,
WNV infection has been found in northern Africa, Israel, India,* Corresponding author.
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since 1999.2,6 Since 1994, the virus has caused frequent outbreaks of
severe neuroinvasive disease in humans and horses in Europe and
the Mediterranean Basin.6
In Turkey, no reports of symptomatic WNV-related disease in
humans or animals were available until 2009, despite published
reports with compelling evidence of widespread virus circulation
in different geographical areas.7 Cases of WNV-related central
nervous system (CNS) diseases have since been reported, as well as
an outbreak in Western Anatolia in 2010.7,8 However, diagnoses
were conﬁrmed via the detection of speciﬁc antibodies against
WNV, and viral RNA detection and characterization have so far
been unsuccessful. In this study, we report the concurrent
occurrence of WNV infections in two cases of equine and one
case of human acute disease, during the winter of 2011. The cases
presented with CNS involvement. A successful virus isolation and
partial genetic characterization was performed for the ﬁrst time in
Turkey.ses. Published by Elsevier Ltd. All rights reserved.
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2.1. Equine cases
Neurological symptoms including muscle weakness in the rear
limbs, muscular tremor, irritability, postural instability, and
movement disorders were identiﬁed in two purebred Arabian
foals (ID# 82 and ID# 88) after initial ﬂu-like symptoms including
slight fever, loss of appetite, and chills. This was recorded in a
stable in Eskisehir Province (398240N-318020E) on January 18, 2011
(Figure 1). The animals were 8 and 9 months old when the disease
was noted. Serum and plasma samples were tested for equine CNS
viruses including equine herpes virus (EHV)-1, EHV-2, EHV-4, and
EHV-5, and WNV nucleic acids by PCR. The foals had made a full
recovery approximately 1 week after disease onset. Following this
episode, a total of 180 randomly-selected serum samples were
collected (on March 5, 2011) from horses of the same herd,
regardless of age or gender, for serological assessment of WNV
exposure within the herd.
2.2. Human case
A 61-year old woman living in uptown Ankara (398560N-
328520E; Figure 1) with no underlying disease other than
hypertension was admitted to Hacettepe University Hospital with
a preliminary diagnosis of viral encephalitis on March 14, 2011.
Her complaints had started 1 week prior to admission with fever
and ﬂu-like symptoms.
Upon admission, she was confused, uncooperative, and
disoriented, with speech fragmentation and mild paraphasic
errors. Furthermore, myoclonic jerks and a resting tremor of the
upper extremities were noted, without signs of meningeal
irritation. No maculopapular or any form of rash was observed
during the disease course. Laboratory evaluation revealed mild
leukocytosis (12  109/l) and elevated cerebrospinal ﬂuid (CSF)
protein (67.81 mg/dl), without pleocytosis or a decrease in
glucose levels. An electroencephalogram (EEG) showed diffuse
slowing of the background rhythm, with sharp slow waves in the
temporal, parietal, and occipital regions of the right hemisphere.
Magnetic resonance imaging (MRI) was within normal limits
except for an incidental right occipital meningioma. Initial
serum–CSF samples and follow-up serum–CSF pairs taken on
days 9 and 20 revealed no evidence of bacterial, mycobacterial, or
fungal infections by culture or rapid antigen assays. All samplesFigure 1. Map showing the areas where human and equine cases of WNV were detected
150 km. ‘E’ indicates equine case locations, ‘H’ indicates the human case location.were also negative in PCR for herpes simplex virus (HSV) type 1/2
and Mycobacterium tuberculosis. The CSF immunoglobulin index
and pathogen-speciﬁc globulin indices for HSV, measles, mumps,
and rubella were also within normal limits. The serum–CSF pairs
were evaluated for WNV and Toscana virus (TOSV) RNA and
serology, as detailed below. The patient was administered
levetiracetam, acyclovir, and ceftriaxone. Her neurological
condition started to improve within a week, and she demonstrat-
ed full cooperation and orientation at the time of discharge,
approximately 3 weeks after admission. She did not have any
history of mosquito, tick, or sandﬂy exposure, transfusion,
outdoor activity, or horseback riding, and had never been
vaccinated for ﬂavivirus infections. She resided in Ankara
Province and had not travelled for the last 7–8 months.
2.3. Nucleic acid tests (NAT) and conﬁrmatory assays
Initially, WNV RNA was sought in all samples via an in-house
real-time PCR assay, as described previously.9 A High Pure Viral
Nucleic Acid Kit (Roche Diagnostics, Germany) was used for the
puriﬁcation of nucleic acids, and a Fermentas RevertAid First
Strand cDNA Synthesis Kit (Thermo Scientiﬁc, Japan) was used for
cDNA synthesis; kits were used in accordance with the manu-
facturer’s instructions. A nested PCR assay was employed for a 240-
bp ﬁnal product in the E-protein coding region of the genomic RNA,
as described previously.10 Dilutions of extracted RNA from culture-
adapted WNV (strain NY99-4132) were used as positive controls in
the PCR assays. The second-round DNA products of the nested PCR
were cleaned via PureLink PCR Puriﬁcation Kit (Invitrogen,
Netherlands) and subjected to nucleotide sequencing. Neighbor-
joining (NJ) analyses of the sequences were carried out for
phylogenetic evaluation using CLC Main Workbench v5.5 (CLCBio,
Denmark). NAT for TOSV and other phleboviruses in serum and CSF
samples from the human patient were performed using generic
and speciﬁc TOSV primers in a nested PCR reaction, as described
previously.11
Buffy coats remaining from the blood samples of the sick horses
and CSF from the patient were inoculated onto Vero cell (ATCC
CCL81) monolayers for virus isolation. Daily microscopic exam-
inations to monitor WNV-indicative cytopathic effects were
performed for 7–9 days post-inoculation. Samples were serially
passaged in Vero cells, and culture ﬂuids (processed as explained
above) were subjected to the nested PCR and subsequent
sequencing, after each culture passage.. The distance between the two locations is indicated with a bar representing about
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For the evaluation of patient samples for WNV and TOSV
immunoglobulins, commercial assays (West Nile virus IgM and IgG
IIFT and ELISA, Toscana Virus IgM and IgG IIFT; Euroimmun,
Germany) were employed as directed by the manufacturer. Patient
samples reactive for WNV immunoglobulins were further tested
via plaque reduction neutralization test (PRNT), as described
previously.12 PRNT was employed for screening and speciﬁcity
conﬁrmation of WNV immunoglobulins in the horse sera. Samples
with neutralizing antibodies against WNV were re-evaluated via
PRNT in serial two-fold serum dilutions starting from 1:5 to assess
the mean antibody titer.
3. Results
3.1. Virological studies
In the human case, all samples were negative in serological
assays and generic PCR for TOSV and phleboviruses. However, the
CSF sample taken on day 1 was reactive for WNV RNA via the
initially performed real-time PCR and subsequent nested PCR. CSF
positive for viral RNA lacked speciﬁc IgM, however IgM in the
paired serum was borderline. While all of the subsequent CSF
samples were negative for viral RNA and immunoglobulins,
subsequent serum samples were observed as reactive for WNV
IgG and were further conﬁrmed for speciﬁcity via PRNT in 1:20
dilution.
In the horse cases, WNV RNA was detectable in blood samples
using both the initial real-time PCR and follow-up nested PCR. The
samples were interpreted as negative by PCR for EHVs.
All human and equine samples with WNV RNA were inoculated
onto Vero cells. While two WNVs were isolated from buffy coat
samples of pre-diagnosed horses, no virus was recovered at the end
of three blind passages of CSF from the human case. The virus titer
was higher (median tissue culture infective dose (TCID50) 10
3/
0.1 ml) in one horse (ID# 82) than in the other (ID# 88) following
initial isolation. Virus isolates were further characterized using a
nested PCR.
Nucleotide sequencing from the sample amplicons and the
corresponding culture supernatants displayed identical sequences,
which have been deposited in GenBank (accession numbers
JN828805 and JN828806). Analysis of nucleotide sequences of
both viruses indicated 99.1% identity with only two nucleotide
substitutions. Phylogenetic analysis (NJ) revealed that the two
viruses detected in the two horses and human were closely related
to lineage 1 WNV strains, particularly to clade 1a (Figure 2).
Despite repeated trials, the length of the sequence obtained from
the human case remained around 118 bases and thus could not be
submitted to GenBank.
3.2. Serosurveillance in horses
PRNT revealed that 57 (31.6%) of 180 horses randomly sampled
had speciﬁc antibodies against WNV. Of the reactive serum
samples, 12 (21%) were found to have an antibody titer of >1:40.
The majority (79%) of the remaining serum samples showed
antibody titers between 1:10 and 1:20.
3.3. Features of the locations where WNV infections were detected
The two centers in which the WNV-related meningoenceph-
alitis cases in the human and in the horses were detected are
located in the mid-Anatolia region of Turkey, approximately
150 km apart (Figure 1). According to the Thornthwaite
classiﬁcation, this region has a semi-arid climate type.13 Itsmost important characteristic is contrasting severe winters and
hot summers with low rainfall levels. The ofﬁcial meteorological
service reports average temperatures (min/max) for February
and March in the region of 1.4 8C (2.9/6.4) and 5.2 8C (0.5/




Continuous but low-level WNV circulation has been reported
from various countries of continental Europe.14 In 2011, the
European Centre for Disease Prevention and Control (ECDC) and
the World Organisation for Animal Health (OIE) declared a total of
86 human cases and 14 cases in horses.15 In Turkey, a country
neighboring the European Union states, previous serosurveillance
data have indicated human WNV exposure in various regions,
including Central, Western (Aegean coast), Southern (Mediterra-
nean coast), and Southeastern Anatolia.7 Conﬁrmed seropreva-
lence rates of 0.56–0.8% have been demonstrated in Central
Anatolia in asymptomatic blood donors.16,17 Moreover, neutraliz-
ing WNV antibodies have been demonstrated in a variety of
mammalian species, including horses.18 However, despite evi-
dence of virus circulation, there are very few documented cases of
WNV infection reported from Turkey.7,8,19–22 Our ﬁndings repre-
sent the ﬁrst WNV sequence data obtained from human CNS
infections and the ﬁrst report of acute WNV infection in horses.
Currently, a limited number of reports of acute WNV infection
and WNV-associated neurological disease from Turkey are
available. Probable WNV-associated encephalitis in humans was
previously suggested in residents of Ankara Province in 2009, and
the diagnosis was further conﬁrmed via PRNT in a 62-year-old
woman.19,20 The symptoms observed in these patients were
similar to those of the current case, in whom symptoms consistent
with relatively mild encephalitis started abruptly following an
unspeciﬁed febrile episode; the patient responded favorably to
supportive therapy and there were no neurological sequelae.
WNV-associated encephalitis was previously identiﬁed in Ankara
Province in a 62-year-old woman in 2009,6 as well as in two men,
aged 56 and 61 years, in 2010.21 The symptoms observed in these
patients were high fever, headache, malaise, confusion, and altered
consciousness, without focal neurological manifestations. CSF
demonstrated lymphocytic pleocytosis and increased protein
levels and the presence of speciﬁc IgM. No signiﬁcant ﬁndings
on EEG or neuroimaging were observed, and all cases responded
favorably to supportive therapy without residual neurological
sequelae. An outbreak of acute WNV infection emerged in 2010 in
Western Anatolia and involved 12 serologically conﬁrmed and 35
probable cases.8 Forty of the 47 cases displayed West Nile disease
with the most common symptoms being fever (100%), headache
(85%), nausea/vomiting (75%), and altered consciousness (57.5%).
However, CSF examination was performed in a limited number of
cases and no data regarding neurological evaluation or nucleic acid
assays were available. In 2011, a fatal case of serologically proven
West Nile disease with tremors and impaired consciousness was
also reported from Ankara Province.22 A distinctive clinical feature
of our patient’s presentation was the presence of myoclonic jerks
and a resting tremor of the upper extremities. Symptoms or
laboratory evidence of encephalitis is observed in about 60% of
persons with West Nile disease,23 and tremors and myoclonus,
where primarily affecting the upper extremities and/or facial
muscles, have been reported in less than a third of cases presenting
with encephalitis.23–25 Thus, cases of CNS infections of presumed
viral etiology presenting with atypical symptoms must also be
evaluated for WNV-related disease.
Figure 2. Phylogenetic analysis of WNV detected in two horses in Turkey. The tree was generated based on the partial sequence of the E protein coding region of the genome by
neighbor-joining (NJ) analysis with 1000 replicates of bootstrap conﬁdence level in CLCBio V5.2, Main Workbench Software (Denmark). Viruses used for the NJ analysis are
described by abbreviations for location/isolation date, followed by the GenBank accession number. Local WNV isolates in the tree are indicated with bold diamonds. JEV GP78
represents outgroup viruses. The numbers at the nodes indicate bootstrapping values. The bar represents nucleotide substitutions per position (118 nt sequence from the human
case (WNV-Hmn-HU11TR):GTCCACCGTGAGTGGTTCATGGACCTCAACCTCCCCTGGAGCAGTGCTGGAAGTACTGTGTGGAGGAACAGAGAGACGTTAATGGAGTTTGAGGAACCACACGC
CACGAAGCAGTCTG).
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in the USA soon after the ﬁrst occurrence of WNV disease in
humans in 1999.26 The most frequent symptom noted in those
cases was ataxia (present in 85%), and about 50% of affected
animals also demonstrated limb weakness, recumbency, and
muscle fasciculation.26 The clinical ﬁndings in the horses of the
current study are in accordance with those previously de-
scribed.26,27
The most critical observation in the current study is the
seasonal occurrence of the clinical disease. Symptomatic human
and equine infections with detectable viral RNA in CSF and buffy
coat, respectively, were identiﬁed in February and March,
unfavorable seasons for WNV transmission due to the diminished
activity of mosquito species. Moreover, the fairly severe winters of
the Central Anatolia region would have been expected to prevent
transmission via vectors.13 Although no evidence for the route of
WNV transmission could be identiﬁed for our cases, the disease can
be speculated to emerge due to overwintering viruses, involving
previously identiﬁed mechanisms of mosquito hibernation. It is
well documented that WNV may biologically persist and evolve in
hibernating mosquitoes.28,29 A study carried out by Clements
demonstrated that female Culex pipiens pipiens mosquitoes
removed from hibernation could ﬂy 4300 meters on average,
with a maximum range of 8674 meters, and were able to blood feed
when appropriate if conditions and hosts were available.30 A
similar mechanism might be responsible for the emergence of the
human and horse infections, as the locations of emergence were
geographically related. Since hibernating blood-fed Culex mosqui-
toes may contain high amounts of WNV, removal from hibernation
and ﬂight over the above-mentioned distances could result in the
efﬁcient transfer of the virus to susceptible dead-end hosts.29–31
Moreover, large capacity stables (e.g., organized stud farms) are
considered to provide good shelters for birds and mosquitoes
during the winter season, and if environmental conditions (heat,
humidity, and nutritional resources) within the stables are
sufﬁcient for the physiological stabilization of the insects,
hibernation may not be required for survival.29–31 An entomologic
survey has already been launched by our group to investigate
potential routes for WNV exposure in the region, and preliminary
ﬁndings indicate the abundance of Culex pipiens pipiens mosquitoes
in the region. However, the exact route of WNV transmission in our
cases remains obscure and needs to be elucidated.
Five genetic lineages of WNV have been identiﬁed, the major
two being lineages 1 and 2.32 The majority of the strains
responsible for the European and Mediterranean Basin outbreaks
belong to lineage 1.14 However, recent data also suggest the
circulation of and symptomatic infections due to lineage 2 strains
as well.14,32 In Greece, a north-western neighbor of Turkey, a large
WNV outbreak occurred in 2010, followed by another in 2011,
resulting in over 250 cases of neuroinvasive disease with 15%
fatality.33,34 WNV lineage 2 sequences were obtained from blood
donors, Culex mosquitoes, and sentinel animals, and the WNV
strain displayed high genetic similarity to the goshawk-Hungary/
04 WNV strain.34,35 Partial sequences obtained from human and
equine infections in this study demonstrated that the causative
virus strains are grouped in lineage 1, clade 1a, and closely related
to North African strains (Figure 2). The origin and routes of
introduction of WNV lineage 1 strains in Turkey are not yet clear,
although several mechanisms including spillover from Eastern
Mediterranean regions can be proposed. Nevertheless, the
presence and distribution of lineage 1 as well as potential activity
of lineage 2 strains in Turkey require further data from genetic
analyses of other strains from various parts of Turkey. Studies are
under way to sequence the whole genome of the present isolates,
which will provide more information about the origin of the strains
in circulation.In conclusion, we have identiﬁed WNV RNA in acute CNS
infections in humans and horses for the ﬁrst time in Turkey. WNV
must be considered in the viral etiology of neuroinvasive infections
in both species. Given that the current study further reports the
occurrence of WNV disease in winter, viral transmission dynamics
and epidemiological features need to be elucidated. WNV has been
responsible for human, equine, and avian epidemic outbreaks in
many regions of the world and remains a serious health problem
with no protective vaccine or effective antiviral treatment.
Moreover, the certain predictability of its possible emergence in
new territories is only now beginning to be realized. Turkey, in
common with several other regions of Europe and Asia, was a
region where convincing evidence originating from virus isolation
or nucleic acid detection in human or animal specimens had been
lacking. Based on RT-PCR sequencing, serological investigation,
and virus isolation studies in horses and one human case, this
study ﬁnally conﬁrms that WNV is indigenous in Turkey.
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